N
Novira Therapeutics
Antiviral drug discovery for HBV and HIV
About Novira Therapeutics
Novira Therapeutics was an antiviral drug discovery company focused on creating first-in-class therapeutics for Hepatitis B (HBV) and HIV. The company was co-founded in 2009 by Dr. Ali H. Munawar and Dr. Osvaldo Flores, who served as President and Chief Scientific Officer. Dr. Munawar holds a PhD in X-ray crystallography and structure-based drug design, and was instrumental in the company's research operations. Dr. Flores previously directed antiviral research at Merck.
The company's primary business was the development of small-molecule, oral drugs that inhibit the viral capsid protein, a novel target involved in multiple stages of viral replication and persistence. This mechanism, focused on disrupting capsid assembly, offered a new approach to combatting these viruses, particularly for HBV which lacks a true cure and HIV which can develop drug resistance. Novira's lead candidate was NVR 3-778, a capsid assembly modulator for treating chronic HBV. By targeting the virus core, these drugs aimed to suppress virus production and replication efficiently.
The company operated on a cost-efficient model to reduce the time and expense of delivering drug candidates with clinical proof of concept. In August 2012, Novira secured $23 million in a Series A financing round to advance its pipeline. In November 2015, Johnson & Johnson announced a definitive agreement to acquire Novira Therapeutics, a transaction that was completed in December 2015. Following the acquisition, Novira became part of the Infectious Diseases & Vaccines Therapeutic Area of the Janssen Pharmaceutical Companies of Johnson & Johnson, which continued the development of NVR 3-778.
Source: Dealroom company dataNews
Open roles
Novira Therapeutics in the Buckingham Township ecosystem
The Novira Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
BioAdvance- RVRobin Hood Ventures
Delaware Crossing Investor Group
Series A4 investors entered at this stage
5AM Ventures
Canaan
Versant Ventures- MFMid Atlantic Angel Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novira Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novira Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

